Skip to main content

Table 2 Baseline characteristics of coagulopathic and non-coagulopathic patients

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

  Coagulopathic patients (n = 136) Non-coagulopathic patients (n = 104) P value
RBCs prior to trial drug, units (n) 8.4 ± 1.6 (134) 8.4 ± 1.4 (98) 1.00
FFP prior to trial drug, ml (n) 922 ± 627 (102) 95 ± 178 (88) <0.001
Platelets prior to trial drug, ml (n) 126 ± 181 (128) 0 ± 0 (100) <0.001
Cryoprecipitate prior to trial drug, ml (n) 28 ± 78 (135) 0 ± 0 (104) <0.001
FFP after trial drug to 48 hours, ml (n) 1,596 ± 1,777 (102) 1,499 ± 1,927 (88) 0.72
Platelets after trial drug to 48 hours, ml (n) 289 ± 341 (127) 319 ± 432 (100) 0.57
Cryoprecipitate after trial drug to 48 hours, ml (n) 56 ± 151 (135) 33 ± 121 (104) 0.19
Injury severity score (n) 30 ± 13 (131) 26 ± 13 (104) 0.02
Temperature, °C (n) 35.1 ± 1.4 (92) 35.2 ± 1.5 (62) 0.68
Mean arterial pressure, mm Hg (n) 76 ± 22 (132) 74 ± 18 (101) 0.45
pH (n) 7.28 ± 0.11 (130) 7.24 ± 0.12 (101) 0.01
Hematocrit, percentage (n) 25 ± 8 (104) 28 ± 9 (83) 0.02
aPTT, seconds (n) 50 ± 25 (79) 54 ± 30 (51) 0.43
PT, seconds (n) 19 ± 6 (90) 21 ± 6 (58) 0.05
Platelet count, × 109 (n) 78 ± 45 (122) 70 ± 47 (98) 0.20
Fibrinogen, g/l (n) 1.3 ± 0.7 (90) 1.2 ± 1.2 (58) 0.57
48-hour mortality, n (percentage) 21 (15) 20 (19) 0.44
30-day mortality, n (percentage) 32 (24) 29 (28) 0.44
  1. Data are mean ± standard deviation or number (percentage). aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; PT, prothrombin time; RBC, red blood cell.